Tissue Regenix has gained Medicare coverage in an additional 10 States covered by Medicare jurisdiction National Government Services (NGS) for the use of DermaPure. NGS, whose jurisdiction covers Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont and Wisconsin, has taken the decision to retire their local coverage determination (LCD) for cellular and tissue based products allowing for DermaPure to be eligible for Medicare reimbursement in outpatient settings across these states. This new coverage adds an additional 7.5 million Medicare beneficiaries and means that Tissue Regenix has now secured Medicare reimbursement in 47 States, totalling 93% of traditional Medicare beneficiaries. DermaPure utilises Tissue Regenix's patented dCELL Technology allowing for a regenerative approach to wound healing and has multiple applications in the treatment of chronic and acute wounds such as diabetic foot ulcers, venous leg ulcers, surgical and trauma wounds.
0.00p (0.00%)delayed 18:15PM